Real-World Sarilumab Use and Rule Testing to Predict Treatment Response in Patients with Rheumatoid Arthritis: Findings from the RISE Registry.
Jeffrey R CurtisHuifeng YunLang ChenStephanie S FordHubert van HoogstratenStefano FioreKerri FordAmy PraestgaardMarkus RehbergErnest H S ChoyPublished in: Rheumatology and therapy (2023)
In real-world setting, sarilumab demonstrated treatment effectiveness, with greater improvements in the most selective population, mirroring phase 3 TNFi-refractory and rule-positive RA patients. Seropositivity appeared a stronger driver for treatment response than CRP, although optimization of the rule in routine practice requires further data.
Keyphrases
- end stage renal disease
- newly diagnosed
- primary care
- randomized controlled trial
- ejection fraction
- rheumatoid arthritis
- chronic kidney disease
- healthcare
- peritoneal dialysis
- prognostic factors
- machine learning
- systemic lupus erythematosus
- quality improvement
- systemic sclerosis
- data analysis
- replacement therapy
- smoking cessation
- interstitial lung disease